ERBB2 and breast carcinoma: For prognostic assessment and clinical decision-making, breast cancer has been divided into three major subtypes based on the presence or absence of molecular markers for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (ERBB2, Erb-B2 Receptor Tyrosine Kinase 2, also known as HER2).